Severe Asthma
Dupilumab reduces severe asthma exacerbations in children
The LIBERTY ASTHMA VOYAGE trial of dupilumab met its primary and key secondary endpoints in children aged 6 to 11 years with uncontrolled moderate to severe asthma, according to a press release.
Biomarker-based adjustment fails to reduce asthma corticosteroid dose
A composite type-2 biomarker corticosteroid adjustment strategy did not result in a greater proportion of patients with severe asthma reducing their corticosteroid dose, according to results published in The Lancet Respiratory Medicine.
Dupilumab long-term data show sustained improvement in moderate to severe asthma
Long-term treatment with dupilumab shows sustained improvement in lung function and reduction in severe exacerbations in patients with moderate to severe asthma, according to new results from a phase 3, open-label extension trial.
Vitamin D supplementation fails to improve time to severe asthma exacerbation in children
Vitamin D supplementation, compared with placebo, did not improve time to severe asthma exacerbation in children with persistent asthma and low vitamin D levels, according to new data published in JAMA.
Tezepelumab reduces exacerbations in broad population of patients with severe asthma
New analyses of the phase 2b PATHWAY study demonstrate that treatment with tezepelumab reduced asthma exacerbations and inflammation in a broad population of patients with severe, uncontrolled asthma.
Two trials provide new insights on fixed-dose subcutaneous reslizumab for severe asthma
Dupilumab reduces severe asthma exacerbations regardless of early improvements in lung function
NEW ORLEANS — In a post hoc analysis of the LIBERTY ASTHMA VENTURE study, treatment with dupilumab resulted in reduced severe asthma exacerbations in patients with oral corticosteroid-dependent severe asthma both with and without early improvements in lung function.
Dupilumab benefit persists regardless of age at asthma onset
NEW ORLEANS — In a post hoc analysis of the LIBERTY ASTHMA QUEST study, treatment with dupilumab reduced severe exacerbations and improved lung function regardless of early or late onset of asthma.
Physicians, patients may overestimate asthma control
NEW ORLEANS — New data demonstrate that physicians and patients with severe asthma frequently overestimated asthma control, suggesting a need for routine use of measures to better inform assessments of control and optimize management.